No profile data available.
GeoVax Labs, Inc. (GOVX) is a healthcare company in the antiviral pharmaceuticals industry, based in Smyrna, United States, with about 19 full-time employees.
It reported revenue of $2.49 million for fiscal year 2025, down 37.1% from fiscal year 2024, and net income of -$21.46 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $2.84 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
GeoVax Labs reported $2.49 million in revenue for fiscal year 2025, down 37.1% from $3.95 million in fiscal year 2024. In Q2 2026 revenue was $0.
$2.84 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Serina Therapeutics, Inc. (SER), NanoViricides, Inc. (NNVC), Cocrystal Pharma, Inc. (COCP), Synairgen plc (SYGGF).